オンコセラピー・サイエンス(株)
株価チャート
2026/08/21 更新株価トレンド
2026/08/21 更新株価・取引詳細
2026/08/21 更新株価
取引
株主構成
2026/08/01 更新財務パフォーマンス
2026/08/23 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥11億 | ¥6億 | ¥8億 | ¥8億 |
| 売上総利益 | ¥0億 | -¥2億 | -¥0億 | ¥0億 |
| 営業利益 | -¥11億 | -¥11億 | -¥8億 | -¥8億 |
| 経常利益 | -¥11億 | -¥13億 | -¥8億 | -¥9億 |
| 当期純利益 | -¥11億 | -¥13億 | -¥8億 | -¥9億 |
| EPS | -¥5.81 | -¥6.05 | -¥3.12 | -¥2.77 |
| 営業利益率 | -97.49% | -183.70% | -106.38% | -100.23% |
| 貸借対照表 | ||||
| 総資産 | ¥15億 | ¥9億 | ¥12億 | ¥24億 |
| 純資産 | ¥9億 | ¥4億 | ¥7億 | ¥21億 |
| 総負債 | ¥7億 | ¥5億 | ¥4億 | ¥2億 |
| 現金 | ¥11億 | ¥5億 | ¥8億 | ¥21億 |
| 有利子負債 | - | - | - | - |
| 自己資本比率 | 56.58% | 40.78% | 63.12% | 90.79% |
| D/Eレシオ | 0.00 | 0.00 | 0.00 | 0.00 |
| キャッシュフロー | ||||
| 営業CF | -¥8億 | -¥12億 | -¥8億 | -¥9億 |
| 投資CF | -¥0億 | -¥0億 | -¥0億 | -¥1億 |
| 財務CF | ¥1億 | ¥7億 | ¥11億 | ¥22億 |
| フリーCF | -¥8億 | -¥12億 | -¥8億 | -¥10億 |
| 効率性 | ||||
| ROE | -130.81% | -364.22% | -111.82% | -42.51% |
| ROA | -74.01% | -148.53% | -70.58% | -38.60% |
最新IR情報
最新ニュース (5件)
企業情報
会社概要
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. The company's development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. Its pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, the company is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
